Brokerages Anticipate Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to Announce $6.83 EPS

Equities analysts forecast that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will post $6.83 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Regeneron Pharmaceuticals’ earnings. The lowest EPS estimate is $5.18 and the highest is $8.23. Regeneron Pharmaceuticals reported earnings per share of $6.84 during the same quarter last year, which would indicate a negative year over year growth rate of 0.1%. The company is scheduled to announce its next earnings report on Wednesday, February 5th.

According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full-year earnings of $23.72 per share for the current fiscal year, with EPS estimates ranging from $22.26 to $25.34. For the next fiscal year, analysts forecast that the company will post earnings of $26.53 per share, with EPS estimates ranging from $23.33 to $30.55. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported $6.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $5.13 by $1.54. Regeneron Pharmaceuticals had a net margin of 28.13% and a return on equity of 24.85%. The business had revenue of $2.05 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same quarter last year, the firm posted $5.87 EPS. The business’s revenue was up 23.2% compared to the same quarter last year.

Several research analysts have weighed in on the stock. Oppenheimer lowered their target price on shares of Regeneron Pharmaceuticals from $480.00 to $430.00 in a research report on Wednesday, November 6th. ValuEngine downgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 25th. JPMorgan Chase & Co. reissued a “hold” rating and set a $375.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 6th. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $344.00 to $358.00 and gave the stock a “market perform” rating in a report on Wednesday, November 6th. Finally, Credit Suisse Group upped their price target on Regeneron Pharmaceuticals from $310.00 to $340.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average price target of $384.74.

Shares of NASDAQ REGN traded up $3.92 during midday trading on Monday, hitting $372.26. The company had a trading volume of 571,347 shares, compared to its average volume of 773,796. The firm has a market capitalization of $40.87 billion, a price-to-earnings ratio of 18.80, a price-to-earnings-growth ratio of 1.62 and a beta of 1.19. Regeneron Pharmaceuticals has a twelve month low of $271.37 and a twelve month high of $442.00. The business has a 50-day simple moving average of $335.70 and a two-hundred day simple moving average of $308.16. The company has a quick ratio of 3.27, a current ratio of 4.03 and a debt-to-equity ratio of 0.07.

Regeneron Pharmaceuticals announced that its board has approved a stock repurchase plan on Tuesday, November 5th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to purchase up to 2.9% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.

In other news, major shareholder Sanofi sold 172,904 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total value of $48,611,959.60. Also, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction on Friday, November 8th. The shares were sold at an average price of $340.44, for a total value of $340,440.00. Following the completion of the sale, the director now owns 10,323 shares in the company, valued at $3,514,362.12. The disclosure for this sale can be found here. Insiders sold 213,923 shares of company stock worth $63,262,696 over the last quarter. Company insiders own 11.84% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. Bridger Capital Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth about $30,000. HM Payson & Co. purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $31,000. Coastal Capital Group Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $38,000. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Regeneron Pharmaceuticals by 104.3% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 143 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 73 shares during the last quarter. Finally, Horan Capital Advisors LLC. acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $47,000. Hedge funds and other institutional investors own 66.48% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Further Reading: Differences Between Momentum Investing and Long Term Investing

Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit